Metabolic Modulators in Cardiovascular Complications of Systemic Lupus Erythematosus

Area of Science:

• Immunology
• Cardiovascular Science
• Metabolism

Background:

• Systemic lupus erythematosus (SLE) primarily affects young women and is linked to increased cardiovascular disease (CVD) mortality.
• Hypertension and vascular complications are prevalent in SLE patients due to immune cell dysregulation and tissue infiltration.
• CD4+ T cell activation and function are critically dependent on cellular metabolism.

Purpose of the Study:

• To review the evidence on whether metabolic modulators can restore immune balance and mitigate cardiovascular complications in SLE.
• To identify knowledge gaps regarding the vasculo-protective effects of targeting immunometabolism in SLE.

Main Methods:

• Literature review of existing evidence on metabolic inhibitors and their effects in SLE.
• Analysis of studies investigating the impact of modulating T cell metabolism on autoimmunity, hypertension, and renal injury.
• Examination of data on endothelial dysfunction and hypertension in SLE mouse models.

Main Results:

• Inhibition of glycolysis, mitochondrial metabolism, and mTORC1 improves endothelial dysfunction and prevents hypertension in SLE mouse models.
• Metabolic modulators show potential for improving cardiovascular outcomes in SLE.
• Limited data exists on the vasculo-protective effects of immunometabolism-targeting drugs in human SLE patients.

Conclusions:

• Modulating cellular metabolism offers a potential therapeutic strategy for managing cardiovascular complications in SLE.
• Further research is needed to explore the clinical application of immunometabolism-targeting drugs for SLE patients.
• Restoring immune system balance through metabolic interventions may be key to improving SLE outcomes.